Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Clinical trial imaging

Harnessing the power of Imaging Phenomics

We’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

iBiopsy

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

Our Spring Corporate Newsletter

We are pleased to share with you our Spring Corporate Newsletter, presenting our most recent announcements and what we did during the first quarter of 2021 and in early Q2. Click below to read the Newsletter!


Read more

Latest press releases

25 February 2021

Median strengthens its iBiopsy® leadership team with the appointment of Thomas Bonnefont as Chief Operating and Commercial Officer and the appointment of Mike Doherty as Sr. Strategy Advisor, Product Development

These two appointments follow a series of first successful achievements for iBiopsy® in 2020 and early 2021. Median prepares to launch its iBiopsy® product development plan, including regulatory aspects, define its go-to-market strategy then expand its iBiopsy® operations globally.

16 February 2021

iBiopsy®: Median Technologies continues its strong positioning in early-stage diagnosis with a new iBiopsy® Clinical Development Plan on Lung Cancer Screening (LCS)

Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide. First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.

9 February 2021

iBiopsy®: Median Technologies inks a major research collaboration agreement with the University of California San Diego (UC San Diego)

The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients. The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy®’s AI technology, applied to liver fibrosis characterization. The Liver Center at UC San Diego is a world-renowned university and healthcare center for liver diseases, with a focus on Non-Alcoholic Fatty Liver Disease (NAFLD) & NASH

14 January 2021

Median Technologies records a 51 % increase of its 2020 annual revenue (unaudited figures)

2020 full year revenue of €13.5 million, increased by 51 % compared to 2019 (€9 million)
As of December 31, 2020, order backlog of €51.7 million, up 35 % compared to December 31, 2019
Cash and cash equivalents of €16.3 million as of December 31, 2020

5 January 2021

Financial Communications Schedule for the First Half of 2021

Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® announces the publication date for its 2020 results.

1/5

Company Update Webcast

We were very pleased to welcome a large number of participants during our webcast held on March 9th, 2021. Fredrik Brag, CEO and founder of Median presented our company’s latest news and outlook and answered questions from the audience.  You didn’t have the opportunity to join? here is the replay! (in French)

Webinars

APRIL 13, 2021

Implementing central reviews for Response Assessment in Neuro-Oncology (RANO) criteria: what are the specificities involved?

If you are an investigator or a sponsor involved in neuro-oncology trials, this 45-minute presentation is for you: we put the focus on RANO criteria and discuss the implementation in independent centralized reviews.

Many questions arise when speaking of RANO and this presentation is a nice opportunity for you to get a detailed overview of these criteria.

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Powering the phenomics revolution

We’re changing the game, transforming the landscape. We’re capturing the power of big data, cloud computing and artificial intelligence to create a new world of possibilities for biopharma compannies and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision and predictive medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median